1. Home
  2. KRRO vs SPRO Comparison

KRRO vs SPRO Comparison

Compare KRRO & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRRO
  • SPRO
  • Stock Information
  • Founded
  • KRRO 2014
  • SPRO 2013
  • Country
  • KRRO United States
  • SPRO United States
  • Employees
  • KRRO N/A
  • SPRO N/A
  • Industry
  • KRRO Biotechnology: Pharmaceutical Preparations
  • SPRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • KRRO Health Care
  • SPRO Health Care
  • Exchange
  • KRRO Nasdaq
  • SPRO Nasdaq
  • Market Cap
  • KRRO 125.4M
  • SPRO 123.0M
  • IPO Year
  • KRRO 2019
  • SPRO 2017
  • Fundamental
  • Price
  • KRRO $15.07
  • SPRO $2.26
  • Analyst Decision
  • KRRO Strong Buy
  • SPRO Buy
  • Analyst Count
  • KRRO 7
  • SPRO 4
  • Target Price
  • KRRO $85.67
  • SPRO $5.00
  • AVG Volume (30 Days)
  • KRRO 122.8K
  • SPRO 796.0K
  • Earning Date
  • KRRO 08-12-2025
  • SPRO 08-12-2025
  • Dividend Yield
  • KRRO N/A
  • SPRO N/A
  • EPS Growth
  • KRRO N/A
  • SPRO N/A
  • EPS
  • KRRO N/A
  • SPRO N/A
  • Revenue
  • KRRO $4,821,000.00
  • SPRO $44,584,000.00
  • Revenue This Year
  • KRRO $65.08
  • SPRO N/A
  • Revenue Next Year
  • KRRO N/A
  • SPRO N/A
  • P/E Ratio
  • KRRO N/A
  • SPRO N/A
  • Revenue Growth
  • KRRO N/A
  • SPRO N/A
  • 52 Week Low
  • KRRO $10.29
  • SPRO $0.51
  • 52 Week High
  • KRRO $98.00
  • SPRO $3.22
  • Technical
  • Relative Strength Index (RSI)
  • KRRO 48.70
  • SPRO 39.84
  • Support Level
  • KRRO $13.34
  • SPRO $2.16
  • Resistance Level
  • KRRO $16.77
  • SPRO $2.44
  • Average True Range (ATR)
  • KRRO 1.46
  • SPRO 0.11
  • MACD
  • KRRO -0.05
  • SPRO -0.04
  • Stochastic Oscillator
  • KRRO 28.68
  • SPRO 26.95

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: